Introduction: With the advent of interferon-free direct-acting antiviral agents (DAAs), the treatment of chronic hepatitis C (CHC) has been revolutionized. Pakistan is among those countries where novel sofosbuvir (SOF) free antiviral agents are not available. Thus, we aimed to determine the virological response and safety of SOF based DAAs in CHC patients on long-term haemodialysis.
Methods: This non-randomized, single-arm, enrolled all hemodialysis patients with chronic hepatitis C; who consented, were treated with SOF in combination either with interferon (IFN group) or daclatasavir (DAC group) and the virological response was assessed as per standard guidelines. Data was analyzed by SPSS version 20.00.
Results: Out of 133 patients, majority were males with mean age of 31.92 ± 9.88years. Majority of patients (50.3%) had genotype 1, while mix genotype was documented in 6 (4.4%) patients. Among these, 60 patients (45.1 %) received standard IFN, SOF and RBV (IFN group). Remaining patients (54.9 %) received SOF, DAC and RBV (DAC group). End of treatment and sustained virological response at 12 weeks post-treatment were achieved in 133 (100%) and 129 (97 %) patients, respectively. The adverse effects were anemia in 58 (43.6 %) patients and raised alanine transaminases was noted in 11 patients.
Conclusion: Sofosbuvir in combination with Interferon or daclatasavir is efficacious and effective treatment regimen for patients on maintenance hemodialysis, especially in resource poor countries.
Azmi AN, Tan SS, Mohamed R. Hepatitis C and kidney disease: an overview and approach to management. World J Hepatol. 2015;7(1):78-92.
Agarwal SK, Bagchi S, Yadav RK. Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen. Kidney Int Rep 2017;2(5):831-835
Mahmud HM, Siddiqui M, Bashir B, Ali SF, Baloch AA, Masroor M. Hemodialysis patients profile at Dow University of Health Sciences, Karachi. Pakistan. Pak J Med Sci. 2014;30(6):1327-30.
Siddiqui AR, Abbas Z, Luck NH, et al. Experience of fibrosing cholestatic hepatitis with hepatitis C virus in kidney transplant recipients. Transplant Proc. 2012 Apr;44(3):721-4.
Hepatitis C guidance: AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report/hcv-testing-and-linkage-care. (accessed August 6th 2018).
Stamm LM, Brainard DM, Mchutchison JG. Sofosbuvir/velpatasvir for patients with chronic genotype 3 HCV infection with compensated cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461-511
Hanif FM, Laeeq SM, Mandhwani RK, ,et al. Effectiveness of sofosbuvir and ribavirin for eradicating hepatitis C virus in renal transplant recipients in Pakistan: where resources are scarce. ExpClin Transplant. 2017;15(Suppl 1):63-7.
Li T, Qu Y, Guo Y, Wang Y, Wang L. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Liver International. 2017;37(7):974-81
Aggarwal A, Yoo ER, Perumpail RB, et al. Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience. J ClinTranslHepatol. 2017;5(1):23-26.
Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36(6):807-16
Farooqi JI, Alam A, Abbas Z, et al. Hep-net opinion about the management of patients with chronic hepatitis C in Pakistan in the era of available DAA. J Postgrad Med Inst 2016; 30(1): 6-14.
Sułowicz W, Radziszewski A, Chowaniec E. Hepatitis C virus infection in dialysis patients. HemodialInt 2007; 11: 286-95
Aguirre valadez J, Garcíajuárez I, Rincónpedrero R, Torre A. Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review. TherClin Risk Manag. 2015;11:329-38.
Rahnavardi M, Hosseini moghaddam SM, Alavian SM. Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures. Am J Nephrol. 2008;28(4):628-40.
Berenguer M. Treatment of chronic hepatitis C in hemodialysis patients. Hepatology. 2008;48(5):1690-9.
Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment PharmacolTher. 2004;20(11-12):1271-7.
Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am SocNephrol. 2000;11(10):1896-902.
Fabrizi F, Messa P. Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?. Expert Rev ClinPharmacol. 2015;8(6):785-93.
Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87.
Gane EJ, Robson RA, Bonacini M, et al. Anti-viral Efficacy and Pharmacokinetics (pk) of Sofosbuvir (sof) in Patients with Severe Renal Impairment.Available at: http://www.natap.org/2014/AASLD/AASLD_85.htm. Accessed January 5, 2019
Bhamidimarri KR, Kalyan ram B, Czul F, et al. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. J Hepatol. 2015;63(3):763-5
Desnoyer A, Pospai D, Lê MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65(1):40-7.
Prabhu RA, Nair S, Pai G, Reddy NP, Suvarna D. Interventions for dialysis patients with hepatitis C virus (HCV) infection. Cochrane Database Syst Rev. 2015;(8):CD007003.